Acceleron to Participate in Three Healthcare Investor Conferences in September

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare investor conferences in September.

Conference Details:

Event:				Citi’s 11th Annual Biotech Conference
Date/Time:				September 7, 2016
Location:				Boston, MA
Event:				Morgan Stanley Global Healthcare Conference
Date/Time:				September 12, 2016 at 3:40 p.m. EDT
Location:				New York, NY
Event:				Leerink Partners Roundtable Series: Rare Disease
Date/Time:				September 28, 2016 at 8:30 a.m. EDT
Location:				New York, NY

Live audio webcasts for the Morgan Stanley Global Healthcare Conference and Leerink Partners Roundtable Series will be available on the Investors page of the Company’s website at www.acceleronpharma.com. A replay of the webcasts will also be available on Acceleron's website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005254/en/

Acceleron Pharma Inc.
Todd James, IRC
Senior Director, Investor Relations and Corporate Communications
617-649-9393
or
Media:
BMC Communications LLC
Brad Miles, 646-513-3125

Source: Acceleron Pharma

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Polygon Joins Digital Pound Lab as XRP Rallies, Best Altcoin To Buy Now AlphaPepe Builds Toward Launch
• New Meme Coins for Late August: $BULLSKI Leads the Fresh Entries